Tailor treatment through targeted, next-generation sequencing

Traditional approaches to classify gynecologic malignancies, including immunohistochemistry and morphology, often fail to provide information on prognostic- and therapy-related associations. Molecular, or genetic, testing can reveal gene variants with clinical significance and improve outcomes for individuals affected by gynecologic cancer.

Mayo Clinic Laboratories’ MayoComplete gynecological cancer panels use next-generation sequencing to evaluate genes with known relevance to diagnosis, prognosis, and treatment of endometrial, ovarian, and sex-cord stromal tumors. An integrated team of gynecologic clinicians, geneticists, and genetic counselors carefully designed our panels to include only clinically actionable genes. Patient-centric, cost-effective, and efficient, our panels provide a detailed picture of a patient’s illness to help understand the best path forward.   

Learn more about our full suite of MayoComplete next-generation sequencing panels for hematologic and oncologic conditions.

MCGYN | MayoComplete Gynecological Cancer Panel, Next-Generation Sequencing, Tumor

• Provides diagnostic, prognostic, and therapeutic insights based on assessment of 49 genes.

MCECP | MayoComplete Endometrial Carcinoma Panel, Next-Generation Sequencing, Tumor

• Provides diagnostic, prognostic, and therapeutic insights based on assessment of 19 genes.

MCOCP | MayoComplete Ovarian, Fallopian Tube, and Peritoneal Cancer Panel, Next-Generation Sequencing, Tumor

• Provides therapeutic insights based on assessment of 14 genes.

POLET | POLE Mutation Analysis, Next-generation Sequencing, Tumor